NASDAQ · HROWL
Healthcare · Medical - Pharmaceuticals
$25.61
Up+$0.05 (+0.19%)
Updated Nov 5, 2026, 7:53 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HROWL
1M range · 0 trading sessions · Daily adjusted prices
HROWL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HROWL.
Company
Market Activity
Research & News
HROWL research
Company profile and research snapshot.
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | BTIG | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 21, 2026 | BTIG | Buy | — |
| May 13, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Sep 26, 2025
Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.
GlobeNewswire Inc. · Sep 26, 2025
Harrow plans to acquire Melt Pharmaceuticals for its MELT-300 sedation therapy, a non-opioid sublingual medication designed to provide rapid sedation for medical procedures. The acquisition aims to expand Harrow's procedural sedation market presence and offer an alternative to traditional IV sedation.
GlobeNewswire Inc. · Sep 8, 2025
Harrow is raising $250 million through senior unsecured notes due in 2030, with plans to repay existing debt and potentially fund future business development opportunities.
GlobeNewswire Inc. · Aug 1, 2025
Pomerantz LLP is investigating potential securities fraud at Harrow, Inc. after the company missed financial estimates in Q1 2025, causing its stock price to drop 4.07%.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HROWL.
